744198-19-4
744198-19-4
Chemical Structure
KCC009
- CAS No.: 744198-19-4
- Formula:C21H22BrN3O5
- Molecular Weight:476.32
IUPAC Name: benzyl ((2S)-1-(((3-bromo-4,5-dihydroisoxazol-5-yl)methyl)amino)-3-(4-hydroxyphenyl)-1-oxopropan-2-yl)carbamate
InChIKey: MRULUIQNANUWTK-ZVAWYAOSSA-N
SMILES: O=C(N[C@H](C(NCC1CC(Br)=NO1)=O)CC2=CC=C(C=C2)O)OCC3=CC=CC=C3
Biological Activity: KCC009, a transglutaminase 2 (TG2) inhibitor, induces p53-independent radiosensitization[1][2].
| Cat. No. | Nom du produit | Pureté | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
KCC009 | 98.06% | KCC009, a transglutaminase 2 (TG2) inhibitor, induces p53-independent radiosensitization. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Sheng Huaying, et al. Transglutaminase 2 Inhibitor KCC009 Induces p53-Independent Radiosensitization in Lung Adenocarcinoma Cells. Med Sci Monit. 2016 Dec 21;22:5041-5048. [Content Brief]
- [2]. L Yuan, et al. Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy. Oncogene [Content Brief]
